Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene.

Aldosterone suppression by dexamethasone, and high 18-hydroxycortisol and 18-oxocortisol levels are used to differentiate glucocorticoid-remediable aldosteronism (GRA) from other forms of primary aldosteronism. These methods are time consuming, expensive, and impractical for large studies. Moreover, diagnosis of GRA requires a confirmatory genetic test. We evaluated 117 patients with primary aldosteronism referred to our centers by the use of a long PCR technique to reveal the chimeric gene of GRA. In 60 of 117 patients, the response of aldosterone to dexamethasone (2 mg/day for 4 days) was also assessed. None of our patients, including 2 pairs of siblings, was positive for the chimeric gene. The results of long PCR were confirmed by Southern blotting. Despite a negative genetic test, 6 patients (1 with aldosterone-producing adenoma and 5 with idiopathic hyperaldosteronism) had plasma aldosterone suppressed by dexamethasone (i.e. < or = 2 ng/dL). Of 117 patients, 43 were identified as having aldosterone-producing adenoma and 74 as having idiopathic hyperaldosteronism. In our experience, the long PCR technique is a reliable and simple test to at least exclude GRA in patients with primary aldosteronism. A short term dexamethasone suppression test of aldosterone can be misleading in identifying GRA. The prevalence of GRA in primary aldosteronism remains to be established.

[1]  R. Lifton,et al.  Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. , 1997, The Journal of clinical endocrinology and metabolism.

[2]  R. Lifton,et al.  Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism. , 1997, The Journal of clinical endocrinology and metabolism.

[3]  G. Chrousos,et al.  Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression , 1997, Clinical endocrinology.

[4]  C. Gomez-Sanchez,et al.  Aldosterone-producing adenomas do not contain glucocorticoid-remediable aldosteronism chimeric gene duplications. , 1996, The Journal of clinical endocrinology and metabolism.

[5]  M. Vallotton.  Primary aldosteronism. Part I Diagnosis of primary hyperaldosteronism , 1996, Clinical endocrinology.

[6]  A. Bachmann,et al.  Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I , 1995, Journal of hypertension.

[7]  X. Jeunemaître,et al.  Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. , 1995, The Journal of clinical investigation.

[8]  M. Schambelan,et al.  [Hyperaldosteronism sensitive to dexamethasone with adrenal adenoma. Clinical, biological and genetic study]. , 1995, Presse medicale.

[9]  M. Stowasser,et al.  A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. , 1995, Biochemical and biophysical research communications.

[10]  K. Curnow,et al.  Genetic recombination as a cause of inherited disorders of aldosterone and cortisol biosynthesis and a contributor to genetic variation in blood pressure , 1995, Steroids.

[11]  M. Stowasser,et al.  Primary aldosteronism—some genetic, morphological, and biochemical aspects of subtypes , 1995, Steroids.

[12]  J. Blumenfeld,et al.  The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. , 1993, The Journal of clinical endocrinology and metabolism.

[13]  J. Lalouel,et al.  Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase , 1992, Nature genetics.

[14]  J. Connell,et al.  Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Lalouel,et al.  A chimaeric llβ-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension , 1992, Nature.

[16]  L. Kornel.  Endocrine hypertension: Comprehensive endocrinology, revised series Henry Burger and David DeKretser, eds. New York, Raven Press, 1989, $99.00 (xv + 280 pages). ISBN 0-891-67587-3 , 1991, Trends in Endocrinology & Metabolism.

[17]  C. Shackleton,et al.  Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. , 1990, American journal of hypertension.

[18]  D. Armanini,et al.  A NEW FAMILY WITH DEXAMETHASONE‐SUPPRESSIBLE HYPERALDOSTERONISM: ALDOSTERONE UNRESPONSIVENESS TO ANGIOTENSIN II , 1985, Clinical endocrinology.

[19]  R. Takeda.  [Steroids and hypertension]. , 1983, Horumon to rinsho. Clinical endocrinology.

[20]  Hoefnagels Wh,et al.  Hazards of long-term dexamethasone treatment in primary aldosteronism. , 1982 .

[21]  A. J. Man in't veld,et al.  ACTH-dependent aldosterone excess due to adrenocortical adenoma: a variant of primary aldosteronism. , 1978, The Journal of clinical endocrinology and metabolism.

[22]  M. Chavarri,et al.  Transient fall and subsequent return of high aldosterone secretion by adrenal adenoma during continued dexamethasone administration. , 1977, The Journal of clinical endocrinology and metabolism.

[23]  C. Gomez-Sanchez,et al.  The role of ACTH in the episodic release of aldosterone in patients with idiopathic adrenal hyperplasia, hypertension, and hyperaldosteronism. , 1976, The Journal of laboratory and clinical medicine.

[24]  M. Schambelan,et al.  Circadian rhythm and effect of posture on plasma aldosterone concentration in primary aldosteronism. , 1976, The Journal of clinical endocrinology and metabolism.

[25]  R. E. Peterson,et al.  Dexamethasone-suppressible hyperaldosteronism. , 1973, The Journal of clinical endocrinology and metabolism.

[26]  D. Sutherland,et al.  Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. , 1966, Canadian Medical Association journal.

[27]  P. Corvol,et al.  The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme , 1997, Nature Structural Biology.

[28]  J. Connell,et al.  Clinical, biochemical and genetic features of five extended kindred's with glucocorticoid-suppressible hyperaldosteronism. , 1995, Endocrine research.

[29]  W. Hoefnagels,et al.  Hazards of long-term dexamethasone treatment in primary aldosteronism. , 1982, The New England journal of medicine.

[30]  T. Kollevold,et al.  [Primary aldosteronism]. , 1969, Nordisk medicin.